Profile data is unavailable for this security.
About the company
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
- Revenue in USD (TTM)5.63m
- Net income in USD-6.08m
- Incorporated1981
- Employees13.00
- LocationInMed Pharmaceuticals IncSUITE 310, 815 W. HASTINGS STREETVANCOUVER V6C 1B4CanadaCAN
- Phone+1 (604) 669-7207
- Fax+1 (778) 945-6800
- Websitehttps://www.inmedpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Petros Pharmaceuticals Inc | 4.12m | -20.64m | 3.38m | 21.00 | -- | 0.4050 | -- | 0.8195 | -6.54 | -6.54 | 1.00 | 0.988 | 0.1529 | 0.6795 | 1.89 | 196,223.30 | -26.18 | -32.43 | -39.25 | -68.05 | 70.21 | 62.04 | -171.23 | -201.70 | 1.26 | -- | 0.4539 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Trevena Inc | 443.00k | -37.03m | 3.42m | 23.00 | -- | -- | -- | 7.72 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Artelo Biosciences Inc | 0.00 | -10.44m | 3.42m | 5.00 | -- | 0.4687 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
Virpax Pharmaceuticals Inc | 0.00 | -17.23m | 3.45m | 7.00 | -- | -- | -- | -- | -13.51 | -13.51 | 0.00 | -0.9847 | 0.00 | -- | -- | 0.00 | -185.82 | -87.52 | -362.29 | -116.56 | -- | -- | -- | -- | -- | -1,596.37 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
Halberd Corp | 281.24k | 25.34k | 3.50m | 3.00 | 2.37 | -- | 137.85 | 12.44 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Avenue Therapeutics Inc | 0.00 | -5.87m | 3.52m | 3.00 | -- | 0.6143 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
ENDRA Life Sciences Inc | 0.00 | -9.57m | 3.57m | 21.00 | -- | 0.0317 | -- | -- | -45.63 | -45.63 | 0.00 | 6.21 | 0.00 | -- | -- | 0.00 | -97.17 | -132.00 | -117.34 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
NovaBay Pharmaceuticals Inc | 12.02m | -15.98m | 3.62m | 24.00 | -- | -- | -- | 0.3007 | -65.73 | -65.91 | 21.94 | -0.4577 | 1.21 | 2.29 | 7.59 | 500,958.30 | -105.75 | -61.51 | -205.52 | -83.89 | 58.55 | 59.99 | -87.67 | -86.47 | 0.4302 | -- | 8.81 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
Ensysce Biosciences Inc | 1.44m | -11.28m | 3.64m | 7.00 | -- | 1.45 | -- | 2.53 | -2.98 | -2.98 | 0.2845 | 0.2218 | 0.3142 | -- | 8.67 | 205,418.60 | -246.46 | -17.68 | -376.98 | -19.42 | -- | -- | -784.43 | -715.78 | -- | -5.93 | 0.235 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
Ainos Inc | 65.12k | -15.41m | 3.74m | 46.00 | -- | 0.1659 | -- | 57.45 | -3.17 | -3.17 | 0.0126 | 2.80 | 0.0019 | 0.7814 | 13.86 | 1,415.65 | -44.29 | -36.36 | -49.13 | -58.33 | -316.62 | 36.82 | -23,664.28 | -813.63 | 1.45 | -55.50 | 0.4016 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
InMed Pharmaceuticals Inc | 5.63m | -6.08m | 3.74m | 13.00 | -- | 0.1514 | -- | 0.6657 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
Bone Biologics Corp | 0.00 | -5.12m | 3.87m | 2.00 | -- | 0.9723 | -- | -- | -10.26 | -10.26 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -94.66 | -98.31 | -119.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -502.76 | -- | -- | -- |
Theriva Biologics Inc | 0.00 | -22.27m | 3.92m | 21.00 | -- | 3.29 | -- | -- | -1.25 | -1.25 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -41.30 | -36.95 | -48.49 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
Helix BioMedix, Inc. | 2.07m | -2.58m | 4.04m | 8.00 | -- | 2.59 | -- | 1.96 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 4.05m | 22.00 | -- | 2.17 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Sabby Management LLCas of 30 Jun 2024 | 307.24k | 3.45% |
Virtu Americas LLCas of 30 Jun 2024 | 86.68k | 0.97% |
XTX Markets LLCas of 30 Jun 2024 | 17.82k | 0.20% |
HRT Financial LLCas of 30 Jun 2024 | 16.00k | 0.18% |
Citadel Securities LLCas of 30 Jun 2024 | 12.10k | 0.14% |
Qube Research & Technologies Ltd.as of 30 Jun 2024 | 200.00 | 0.00% |
BofA Securities, Inc.as of 30 Jun 2024 | 100.00 | 0.00% |
TD Waterhouse Canada, Inc.as of 30 Jun 2024 | 85.00 | 0.00% |
Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 32.00 | 0.00% |
RBC Dominion Securities, Inc. (Investment Management)as of 30 Jun 2024 | 25.00 | 0.00% |